For the first half of 2025, product sales totaled $85 million, with additional research and development revenues of $2 million for Q2 and $3 million for the six months ended June 30, 2025.
Pretax operating income for Q2 2025 was approximately $46 million, with net income of about $35 million and fully diluted EPS of $0.49 for both the quarter and the six-month period.
SIGA maintained a strong balance sheet with approximately $182 million in cash and no debt as of June 30, 2025.
SIGA reported product sales of $79 million for Q2 2025, consisting of $53 million from oral TPOXX and $26 million from IV TPOXX delivered to the U.S. Strategic National Stockpile.
There remain $26 million of outstanding orders from the U.S. government related to the 19C contract, targeted for delivery in 2026.
Gross margin expanded to 52% in Q2, up year-over-year and sequentially, driven primarily by pricing and partially offset by product mix and non-manufacturing costs.
International sales performance exceeded expectations despite a $10 million headwind from distributor inventory adjustments ahead of a 2026 direct sales transition.
Operating expenses grew 10% year-over-year due to SG&A investments, while R&D expenses remained flat.
Tandem Diabetes Care achieved record second quarter 2025 sales of $241 million worldwide, with $170 million in the U.S. and $70 million internationally.
The company ended Q2 with $315 million in cash and investments, having settled $41 million in convertible notes and paid $8 million towards a $36 million patent settlement.
Year-to-date worldwide sales reached $475 million, representing 15% growth driven by pump and supply volumes and a 4% pricing improvement year-over-year.
Dafinchi